In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ArQule, Inc.

http://www.arqule.com

Latest From ArQule, Inc.

Finance Watch: Two Years Later, $212m More Cash For Omega’s New Life Science Fund

Private Company Edition: Omega Funds closed its seventh venture capital fund, far exceeding its $500m goal. Also, Anaveon raised a CHF110m ($119.8m) series B round, Ambys brought its series A total to $107m with $47m in additional investment and Mythic launched with a $103m series B round.

Financing Innovation

Better Late Than Never: German Medtechs Make The Case For Practical MDR Improvements

A regulatory system that cannot function as intended, even with an extra year for preparation, will become mandatory in the EU next week. German medtechs suggest a route forward.

Regulation EU

EMA Says Yes To Eight New Medicines, Holds Fire On Others

The European Medicines Agency today announced the new medicines it believes should be approved for use across the EU.

Europe Approvals

Basilea Looks To Progress Cancer Pipeline As It Expands Zevtera Use

Switzerland’s Basilea Pharmaceutica is progressing its lead oncology candidates and a second late-stage US clinical trial of ceftobiprole in difficult-to-treat infections.

Infectious Diseases Research & Development
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
      • Molecular Diversity
  • Other Names / Subsidiaries
    • Cyclis Pharmaceuticals, Inc.
UsernamePublicRestriction

Register